Prokarium Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.93M

  • Investors
  • 11

Prokarium General Information

Description

Operator of a biopharmaceutical company intended for developing bacterial immunotherapies for cancer. The company's proprietary technology naturally homes to tumors, stimulates anti-tumor immune responses, and can be programmed to deliver therapeutic agents directly inside the tumor microenvironment, targeting non-muscle invasive bladder cancer, enabling the healthcare industry to treat patients with cancers whose tumors resist or do not respond well to current immunotherapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • London Bioscience Innovation Centre
  • 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • London Bioscience Innovation Centre
  • 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom

Prokarium Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prokarium Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 02-Dec-2025 $7.93M Completed Clinical Trials - Phase 1
9. Accelerator/Incubator 01-Jan-2024 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series B2) 09-Feb-2023 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 27-Oct-2020 Completed Clinical Trials - Phase 1
6. Grant 08-Oct-2019 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 26-Feb-2018 Completed Clinical Trials - Phase 1
4. Grant 25-Jul-2016 Completed Clinical Trials - Phase 1
3. Grant 03-Aug-2015 Completed Clinical Trials - Phase 1
2. Grant 11-Mar-2013 $609K $12.5M Completed Startup
1. Seed Round 01-Jan-2012 $12.5M $12.5M Completed Startup
To view Prokarium’s complete valuation and funding history, request access »

Prokarium Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 169,305 $0.013147 $34.22 $34.22 1x $34.22 3.26%
Ordinary 670,000 $0.013147 $36.53 $36.53 1x $36.53 12.91%
To view Prokarium’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Prokarium Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended for developing bacterial immunotherapies for cancer. The company's prop
Drug Discovery
London, United Kingdom
18 As of 2025

Berkeley, CA
 

Allschwil, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prokarium Competitors (29)

One of Prokarium’s 29 competitors is Actym Therapeutics, a Venture Capital-Backed company based in Berkeley, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Actym Therapeutics Venture Capital-Backed Berkeley, CA
T3 Pharmaceuticals Formerly VC-backed Allschwil, Switzerland
Redbiotec Venture Capital-Backed Schlieren, Switzerland
Genocea Biosciences Formerly VC-backed Cambridge, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 29 competitors. Get the full list »

Prokarium Patents

Prokarium Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202502951-D0 Nucleic acid construct Pending 28-Feb-2025
WO-2026180692-A1 Nucleic acid construct Pending 28-Feb-2025
GB-202502950-D0 Quorum sensing Pending 28-Feb-2025
WO-2026180700-A1 Quorum sensing circuit Pending 28-Feb-2025
GB-202411952-D0 Flagellar secretion systems Inactive 14-Aug-2024
To view Prokarium’s complete patent history, request access »

Prokarium Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prokarium Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Grow London Accelerator/Incubator
Ginkgo Bioworks VC-Backed Company Minority
British Business Bank Lender/Debt Provider Minority
Wellcome Trust Limited Partner Minority
Korea Investment Partners Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Prokarium FAQs

  • When was Prokarium founded?

    Prokarium was founded in 2012.

  • Where is Prokarium headquartered?

    Prokarium is headquartered in London, United Kingdom.

  • What is the size of Prokarium?

    Prokarium has 18 total employees.

  • What industry is Prokarium in?

    Prokarium’s primary industry is Drug Discovery.

  • Is Prokarium a private or public company?

    Prokarium is a Private company.

  • What is the current valuation of Prokarium?

    The current valuation of Prokarium is .

  • What is Prokarium’s current revenue?

    The current revenue for Prokarium is .

  • How much funding has Prokarium raised over time?

    Prokarium has raised $90.4M.

  • Who are Prokarium’s investors?

    Grow London, Ginkgo Bioworks, British Business Bank, Wellcome Trust, and Korea Investment Partners are 5 of 11 investors who have invested in Prokarium.

  • Who are Prokarium’s competitors?

    Actym Therapeutics, T3 Pharmaceuticals, Redbiotec, Genocea Biosciences, and Adaptimmune Therapeutics are some of the 29 competitors of Prokarium.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process